10-Q 1 kequ-q210xq201910x31x19.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
FORM 10-Q
_________________________

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2019
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________
Commission file number 0-5286
_________________________
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
_________________________

Delaware |  | 38-0715562
(State or other jurisdiction of incorporation or organization) |  | (IRS Employer Identification No.)
2700 West Front Street Statesville, North Carolina |  | 28677-2927
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol(s) Name of Exchange on which registered
Common Stock,$2.50 par value KEQU NASDAQ Global Market
_________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☐ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☒
|  |  |  | Emerging growth company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of December 10, 2019, the registrant had outstanding 2,750,143 shares of Common Stock.

KEWAUNEE SCIENTIFIC CORPORATION
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2019

|  | Page Number
PART I. FINANCIAL INFORMATION |
Item 1. | Financial Statements |
| Condensed Consolidated Statements of Operations (unaudited) – Three and Six Months Ended October 31, 2019 and 2018 | 1
| Condensed Consolidated Statements of Comprehensive Income (unaudited) – Three and Six Months Ended October 31, 2019 and 2018 | 2
| Condensed Consolidated Statement of Stockholders’ Equity (unaudited) – Three and Six Months Ended October 31, 2019 and 2018 | 3
| Condensed Consolidated Balance Sheets – October 31, 2019 (unaudited) and April 30, 2019 | 4
| Condensed Consolidated Statements of Cash Flows (unaudited) – Six Months Ended October 31, 2019 and 2018 | 5
| Notes to Condensed Consolidated Financial Statements (unaudited) | 6
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 13
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 15
Item 4. | Controls and Procedures | 15
PART II. OTHER INFORMATION |
Item 6. | Exhibits | 16
SIGNATURES | 17

i

Part 1. Financial Information

Item 1. | Financial Statements

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
($ and shares in thousands, except per share amounts)

| Three Months Ended October 31, |  | Six Months Ended October 31,
| 2019 |  | 2018 |  | 2019 |  | 2018
Net sales | $ | 39,722 |  |  | $ | 37,278 |  |  | $ | 79,058 |  |  | $ | 79,430 |
Cost of products sold | 33,406 |  |  | 29,614 |  |  | 65,796 |  |  | 64,183 |
Gross profit | 6,316 |  |  | 7,664 |  |  | 13,262 |  |  | 15,247 |
Operating expenses | 6,355 |  |  | 5,963 |  |  | 12,525 |  |  | 11,726 |
Operating earnings (loss) | (39 | ) |  | 1,701 |  |  | 737 |  |  | 3,521 |
Other income | 16 |  |  | 150 |  |  | 72 |  |  | 314 |
Interest expense, net | (135 | ) |  | (91 | ) |  | (302 | ) |  | (182 | )
Earnings (loss) before income taxes | (158 | ) |  | 1,760 |  |  | 507 |  |  | 3,653 |
Income tax expense | 2,003 |  |  | 388 |  |  | 2,172 |  |  | 783 |
Net earnings (loss) | (2,161 | ) |  | 1,372 |  |  | (1,665 | ) |  | 2,870 |
Less: net earnings attributable to the noncontrolling interest | 17 |  |  | 40 |  |  | 42 |  |  | 49 |
Net earnings (loss) attributable to Kewaunee Scientific Corporation | $ | (2,178 | ) |  | $ | 1,332 |  |  | $ | (1,707 | ) |  | $ | 2,821 |
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders |  |  |  |  |  |  |
Basic | $ | (0.79 | ) |  | $ | 0.49 |  |  | $ | (0.62 | ) |  | $ | 1.03 |
Diluted | $ | (0.79 | ) |  | $ | 0.48 |  |  | $ | (0.62 | ) |  | $ | 1.01 |
Weighted average number of common shares outstanding |  |  |  |  |  |  |
Basic | 2,750 |  |  | 2,743 |  |  | 2,750 |  |  | 2,740 |
Diluted | 2,750 |  |  | 2,800 |  |  | 2,750 |  |  | 2,802 |

See accompanying notes to condensed consolidated financial statements.
1

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
($ in thousands)

| Three Months Ended October 31, |  | Six Months Ended October 31,
| 2019 |  | 2018 |  | 2019 |  | 2018
Net earnings (loss) | $ | (2,161 | ) |  | $ | 1,372 |  |  | $ | (1,665 | ) |  | $ | 2,870 |
Other comprehensive income (loss), net of tax: |  |  |  |  |  |  |
Foreign currency translation adjustments | (179 | ) |  | (725 | ) |  | 17 |  |  | (1,113 | )
Change in fair value of cash flow hedge | 2 |  |  | 1 |  |  | 1 |  |  | 5 |
Other comprehensive income (loss) | (177 | ) |  | (724 | ) |  | 18 |  |  | (1,108 | )
Comprehensive income (loss), net of tax | (2,338 | ) |  | 648 |  |  | (1,647 | ) |  | 1,762 |
Less: comprehensive income attributable to the noncontrolling interest | 17 |  |  | 40 |  |  | 42 |  |  | 49 |
Comprehensive income (loss) attributable to Kewaunee Scientific Corporation | $ | (2,355 | ) |  | $ | 608 |  |  | $ | (1,689 | ) |  | $ | 1,713 |

See accompanying notes to condensed consolidated financial statements.
2

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
($ in thousands, except share and per share amounts)

| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity
Balance at April 30, 2019 | $ | 6,875 |  |  | $ | 3,133 |  |  | $ | (53 | ) |  | $ | 43,552 |  |  | $ | (6,407 | ) |  | $ | 47,100 |
Net earnings attributable to Kewaunee Scientific Corporation | — |  |  | — |  |  | — |  |  | 471 |  |  | — |  |  | 471 |
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | 195 |  |  | 195 |
Cash dividends paid, $0.19 per share | — |  |  | — |  |  | — |  |  | (522 | ) |  | — |  |  | (522 | )
Stock based compensation | 9 |  |  | 51 |  |  | — |  |  | — |  |  | — |  |  | 60 |
Balance at July 31, 2019 | $ | 6,884 |  |  | $ | 3,184 |  |  | $ | (53 | ) |  | $ | 43,501 |  |  | $ | (6,212 | ) |  | $ | 47,304 |
Net earnings (loss) attributable to Kewaunee Scientific Corporation | — |  |  | — |  |  | — |  |  | (2,178 | ) |  | — |  |  | (2,178 | )
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | (177 | ) |  | (177 | )
Cash dividends paid, $0.19 per share | — |  |  | — |  |  | — |  |  | (523 | ) |  | — |  |  | (523 | )
Stock based compensation | — |  |  | 42 |  |  | — |  |  | — |  |  | — |  |  | 42 |
Balance at October 31, 2019 | $ | 6,884 |  |  | $ | 3,226 |  |  | $ | (53 | ) |  | $ | 40,800 |  |  | $ | (6,389 | ) |  | $ | 44,468 |

| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity
Balance at April 30, 2018 | $ | 6,841 |  |  | $ | 3,006 |  |  | $ | (53 | ) |  | $ | 43,836 |  |  | $ | (5,900 | ) |  | $ | 47,730 |
Net earnings attributable to Kewaunee Scientific Corporation | — |  |  | — |  |  | — |  |  | 1,489 |  |  | — |  |  | 1,489 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (384 | ) |  | (384 | )
Cash dividends paid, $0.17 per share | — |  |  | — |  |  | — |  |  | (465 | ) |  | — |  |  | (465 | )
Stock options exercised, 9,250 shares | 13 |  |  | (13 | ) |  | — |  |  | — |  |  | — |  |  | — |
Stock based compensation | 7 |  |  | 99 |  |  | — |  |  | — |  |  | — |  |  | 106 |
Cumulative adjustment for ASC 606, net of tax | — |  |  | — |  |  | — |  |  | 217 |  |  | — |  |  | 217 |
Balance at July 31, 2018 | $ | 6,861 |  |  | $ | 3,092 |  |  | $ | (53 | ) |  | $ | 45,077 |  |  | $ | (6,284 | ) |  | $ | 48,693 |
Net earnings attributable to Kewaunee Scientific Corporation | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 1,332 |  |  | $ | — |  |  | $ | 1,332 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (724 | ) |  | (724 | )
Cash dividends paid, $0.19 per share | — |  |  | — |  |  | — |  |  | (521 | ) |  | — |  |  | (521 | )
Stock options exercised, 5,800 shares | 8 |  |  | (8 | ) |  | — |  |  | — |  |  | — |  |  | — |
Stock based compensation | — |  |  | 140 |  |  | — |  |  | — |  |  | — |  |  | 140 |
Cumulative adjustment for ASC 606, net of tax | — |  |  | — |  |  | — |  |  | 671 |  |  | — |  |  | 671 |
Balance at October 31, 2018 | $ | 6,869 |  |  | $ | 3,224 |  |  | $ | (53 | ) |  | $ | 46,559 |  |  | $ | (7,008 | ) |  | $ | 49,591 |

See accompanying notes to condensed consolidated financial statements.
3

Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
($ and shares in thousands, except per share amounts)

| October 31, 2019 |  | April 30, 2019
| (Unaudited) |  |
Assets |  |  |
Current Assets: |  |  |
Cash and cash equivalents | $ | 7,647 |  |  | $ | 10,647 |
Restricted cash | 1,951 |  |  | 509 |
Receivables, less allowance; $427; $361, on each respective date | 32,017 |  |  | 33,259 |
Inventories | 14,778 |  |  | 17,206 |
Prepaid expenses and other current assets | 4,674 |  |  | 3,736 |
Total Current Assets | 61,067 |  |  | 65,357 |
Property, plant and equipment, at cost | 57,359 |  |  | 56,676 |
Accumulated depreciation | (41,475 | ) |  | (40,214 | )
Net Property, Plant and Equipment | 15,884 |  |  | 16,462 |
Right of use assets | 10,082 |  |  | — |
Deferred income taxes | 102 |  |  | 1,829 |
Other assets | 3,187 |  |  | 3,575 |
Total Other Assets | 13,371 |  |  | 5,404 |
Total Assets | $ | 90,322 |  |  | $ | 87,223 |
Liabilities and Stockholders’ Equity |  |  |
Current Liabilities: |  |  |
Short-term borrowings and interest rate swaps | $ | 6,760 |  |  | $ | 9,513 |
Current portion of long-term debt | — |  |  | 1,167 |
Current portion of capital lease liability | 18 |  |  | 17 |
Current portion of operating lease liabilities | 1,401 |  |  | — |
Accounts payable | 13,836 |  |  | 15,190 |
Employee compensation and amounts withheld | 3,788 |  |  | 3,737 |
Deferred revenue | 2,032 |  |  | 1,599 |
Other accrued expenses | 2,391 |  |  | 1,510 |
Total Current Liabilities | 30,226 |  |  | 32,733 |
Long-term debt | — |  |  | 97 |
Long-term portion of capital lease liability | 123 |  |  | 132 |
Long-term portion of operating lease liabilities | 8,513 |  |  | — |
Accrued pension and deferred compensation costs | 5,592 |  |  | 5,878 |
Other non-current liabilities | 878 |  |  | 680 |
Total Liabilities | 45,332 |  |  | 39,520 |
Commitments and Contingencies |  |  |
Stockholders’ Equity: |  |  |
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,753 shares; 2,750 shares; – Outstanding – 2,750 shares; 2,747 shares, on each respective date | 6,884 |  |  | 6,875 |
Additional paid-in-capital | 3,226 |  |  | 3,133 |
Retained earnings | 40,800 |  |  | 43,552 |
Accumulated other comprehensive loss | (6,389 | ) |  | (6,407 | )
Common stock in treasury, at cost, 3 shares, on each date | (53 | ) |  | (53 | )
Total Kewaunee Scientific Corporation Stockholders’ Equity | 44,468 |  |  | 47,100 |
Noncontrolling interest | 522 |  |  | 603 |
Total Stockholders’ Equity | 44,990 |  |  | 47,703 |
Total Liabilities and Stockholders’ Equity | $ | 90,322 |  |  | $ | 87,223 |

See accompanying notes to condensed consolidated financial statements.
4

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
($ in thousands)

| Six Months Ended October 31,
| 2019 |  | 2018
Cash flows from operating activities: |  |  |
Net earnings (loss) | $ | (1,665 | ) |  | $ | 2,870 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: |  |  |
Depreciation | 1,292 |  |  | 1,263 |
Bad debt provision | 72 |  |  | 20 |
Stock based compensation expense | 115 |  |  | 275 |
Provision for deferred income taxes | 1,727 |  |  | 143 |
Change in assets and liabilities: |  |  |
Receivables | 1,171 |  |  | 2,855 |
Inventories | 2,428 |  |  | 565 |
Accounts payable and other accrued expenses | (223 | ) |  | (4,202 | )
Deferred revenue | 433 |  |  | (321 | )
Other, net | (854 | ) |  | (1,167 | )
Net cash provided by operating activities | 4,496 |  |  | 2,301 |
Cash flows from investing activities: |  |  |
Capital expenditures | (715 | ) |  | (1,311 | )
Net cash used in investing activities | (715 | ) |  | (1,311 | )
Cash flows from financing activities: |  |  |
Dividends paid | (1,045 | ) |  | (986 | )
Dividends paid to noncontrolling interest in subsidiaries | (89 | ) |  | — |
Proceeds from short-term borrowings | 31,456 |  |  | 34,135 |
Repayments on short-term borrowings | (34,209 | ) |  | (33,362 | )
Payments on long-term debt and lease obligations | (1,273 | ) |  | (583 | )
Net proceeds from exercise of stock options | (14 | ) |  | (29 | )
Net cash used in financing activities | (5,174 | ) |  | (825 | )
Effect of exchange rate changes on cash and cash equivalents | (165 | ) |  | (967 | )
Increase (decrease) in cash, cash equivalents and restricted cash | (1,558 | ) |  | (802 | )
Cash, cash equivalents and restricted cash, beginning of period | 11,156 |  |  | 10,958 |
Cash, cash equivalents and restricted cash, end of period | $ | 9,598 |  |  | $ | 10,156 |

See accompanying notes to condensed consolidated financial statements.
5

Kewaunee Scientific Corporation
Notes to Condensed Consolidated Financial Statements
(unaudited)
A. Financial Information
The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2019 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The condensed consolidated balance sheet as of April 30, 2019 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles ("GAAP") for complete financial statements.
The preparation of the interim condensed consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
B. Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the periods ended October 31, 2019 and 2018, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders.
In accordance with ASU 2016-18, Statement of Cash Flows: Restricted Cash, the Company includes restricted cash along with the cash balance for presentation in the consolidated statements of cash flows. The reconciliation between the consolidated balance sheet and the consolidated statement of cash flows is as follows:

|  | October 31, 2019 |  | October 31, 2018
Cash and cash equivalents |  | $ | 7,647 |  |  | $ | 9,477 |
Restricted cash |  | 1,951 |  |  | 679 |
Total cash, cash equivalents and restricted cash |  | $ | 9,598 |  |  | $ | 10,156 |

C. Revenue Recognition
The Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company’s revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company’s revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract.
Disaggregated Revenue
A summary of net sales transferred to customers at a point in time and over time for the periods ended October 31, 2019 and October 31, 2018 is as follows (in thousands):
6

| Three Months Ended October 31, 2019 |  | Three months ended October 31, 2018
| Domestic |  | International |  | Total |  | Domestic |  | International |  | Total
Over Time | $ | 29,950 |  |  | $ | 8,138 |  |  | $ | 38,088 |  |  | $ | 28,311 |  |  | $ | 6,656 |  |  | $ | 34,967 |
Point in Time | 1,634 |  |  | — |  |  | 1,634 |  |  | 2,311 |  |  | — |  |  | 2,311 |
| $ | 31,584 |  |  | $ | 8,138 |  |  | $ | 39,722 |  |  | $ | 30,622 |  |  | $ | 6,656 |  |  | $ | 37,278 |

| Six Months Ended October 31, 2019 |  | Six Months Ended October 31, 2018
| Domestic |  | International |  | Total |  | Domestic |  | International |  | Total
Over Time | $ | 58,185 |  |  | $ | 18,187 |  |  | $ | 76,372 |  |  | $ | 62,559 |  |  | $ | 12,738 |  |  | $ | 75,297 |
Point in Time | 2,686 |  |  | — |  |  | 2,686 |  |  | 4,133 |  |  | — |  |  | 4,133 |
| $ | 60,871 |  |  | $ | 18,187 |  |  | $ | 79,058 |  |  | $ | 66,692 |  |  | $ | 12,738 |  |  | $ | 79,430 |

Contract Balances
The closing and opening balances of contract assets arising from contracts with customers which were recorded as unbilled receivables were $5,116,000 at October 31, 2019 and $4,589,000 at April 30, 2019. The closing and opening balances of contract liabilities arising from contracts with customers were $2,032,000 at October 31, 2019 and $1,599,000 at April 30, 2019. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed on the consolidated balance sheets and in the notes to the consolidated financial statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately all of the contract liability balances at April 30, 2019 and October 31, 2019 are expected to be recognized as revenue during the respective succeeding 12 months.
D. Inventories
The Company measures inventory using the first-in, first-out ("FIFO") method at the lower of cost and net realizable value. Inventories consisted of the following (in thousands):

| October 31, 2019 |  | April 30, 2019
Finished products | $ | 3,068 |  |  | $ | 4,139 |
Work in process | 1,878 |  |  | 2,179 |
Raw materials | 9,832 |  |  | 10,888 |
| $ | 14,778 |  |  | $ | 17,206 |

The Company’s International subsidiaries’ inventories were $2,005,000 at October 31, 2019 and $1,863,000 at April 30, 2019 and are included in the above tables.
7

E. Fair Value of Financial Instruments
The Company’s financial instruments consist primarily of cash and equivalents, mutual funds, cash surrender value of life insurance policies, term loans and short-term borrowings. The carrying value of these assets and liabilities approximate their fair value. The following tables summarize the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 and April 30, 2019 (in thousands):

|  | October 31, 2019
Financial Assets |  | Level 1 |  | Level 2 |  | Total
Trading securities held in non-qualified compensation plans (1) |  | $ | 2,514 |  |  | $ | — |  |  | $ | 2,514 |
Cash surrender value of life insurance policies (1) |  | — |  |  | 76 |  |  | 76 |
Total |  | $ | 2,514 |  |  | $ | 76 |  |  | $ | 2,590 |
Financial Liabilities |  |  |  |  |  |
Non-qualified compensation plans (2) |  | $ | — |  |  | $ | 3,007 |  |  | $ | 3,007 |
Total |  | $ | — |  |  | $ | 3,007 |  |  | $ | 3,007 |

|  | April 30, 2019
Financial Assets |  | Level 1 |  | Level 2 |  | Total
Trading securities held in non-qualified compensation plans (1) |  | $ | 3,057 |  |  | $ | — |  |  | $ | 3,057 |
Cash surrender value of life insurance policies (1) |  | — |  |  | 76 |  |  | 76 |
Total |  | $ | 3,057 |  |  | $ | 76 |  |  | $ | 3,133 |
Financial Liabilities |  |  |  |  |  |
Non-qualified compensation plans (2) |  | $ | — |  |  | $ | 3,519 |  |  | $ | 3,519 |
Interest rate swap derivatives |  | — |  |  | 1 |  |  | 1 |
Total |  | $ | — |  |  | $ | 3,520 |  |  | $ | 3,520 |

(1) | The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.

(2) | Plan liabilities are equal to the individual participants’ account balances and other earned retirement benefits.

F. Derivative Financial Instruments
The Company records derivatives on the condensed consolidated balance sheets at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company does not enter into derivative instruments for speculative purposes. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $3,450,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.875% for the period beginning May 1, 2013 and ending August 1, 2017. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $2,600,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.37% for the period beginning August 1, 2017 and ending May 1, 2020. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $1,218,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 3.07% for the period beginning November 3, 2014 and ending May 1, 2020. The Company entered into these interest rate swap arrangements to mitigate future interest rate risk associated with its long-term debt and has designated these as cash flow hedges. In September 2019, the Company terminated the interest rate swap arrangements in conjunction with the payoff of the outstanding long-term debt.
G. Long-term Debt and Other Credit Arrangements
At October 31, 2019, advances of $6.8 million were outstanding under the Company’s revolving credit facility, compared to advances of $9.5 million outstanding as of April 30, 2019. The Company had standby letters of credit outstanding of $344,000 at October 31, 2019 compared to standby letters of credit outstanding of $5.2 million at April 30, 2019. Amounts available under the $20 million revolving credit facility were $12.9 million and $5.3 million at October 31, 2019 and April 30, 2019, respectively.
8

At April 30, 2019, the Company was not in compliance with all of the financial covenants under the revolving credit facility. The Company received a waiver from its lender with respect to this noncompliance pursuant to a waiver letter executed on June 19, 2019 ("the Waiver Letter"). In connection with the Waiver Letter, the Company entered into a Security Agreement pursuant to which the Company granted a security interest in substantially all of its assets to secure its obligations under the Loan Agreement. On July 9, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change in the financial covenants set forth in the Loan Agreement. This amendment did not change the amount of availability provided by the Company’s Line of Credit.
In September 2019, the Company paid off its term loan and terminated its interest rate swap agreements. On December 13, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change to an asset based lending arrangement based on eligible accounts receivable and inventory, with the available amount not to exceed $20 million through January 31, 2020, and with such maximum amount reduced to $15 million thereafter. This amendment replaced the prior financial covenants with new financial covenants, including minimum monthly liquidity and EBITDA requirements. Additionally, a requirement for the repatriation of foreign cash and restrictions on the payment of dividends were added. At October 31, 2019, the Company was in compliance with all of the then-applicable financial covenants of the agreement.
H. Leases
On May 1, 2019, the Company adopted Accounting Standards Update ("ASU") No. 2016-02, Leases, and all subsequently issued clarifying guidance. Under the new guidance, lessees are required to recognize lease assets and lease liabilities for the rights and obligations created by leased assets previously classified as operating leases. In July 2018, the Financial Accounting Standards Board ("FASB") issued ASU No. 2018-11, which permitted entities to record the impact of adoption using a modified retrospective method with any cumulative effect as an adjustment to retained earnings (accumulated deficit) as opposed to restating comparative periods for the effects of applying the new standard. The Company elected this transition approach; therefore, the Company’s prior period reported results are not restated to include the impact of this adoption. In addition, the Company elected the package of three transition practical expedients which alleviate the requirements to reassess embedded leases, lease classification and initial direct costs for leases that commenced prior to the adoption date. The Company has elected to use the short-term lease recognition exemption for all asset classes. This means, for those leases that qualify, the Company will not recognize right-of-use ("ROU") assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets. The adoption of this standard did not affect the Condensed Consolidated Statements of Operations and therefore, no cumulative effect adjustment was recorded. The adoption of this standard also did not materially affect the Condensed Consolidated Statements of Cash Flows.
The Company has operating type leases for real estate and equipment in both the U.S. and internationally and a financing lease for a truck in the U.S. At October 31, 2019, ROU assets totaled $10,082,000. Included in the ROU assets was a finance lease with a net value of $134,000 with accumulated amortization totaling $25,000. Operating cash paid to settle lease liabilities was $354,000 for the period ended October 31, 2019. The Company’s leases have remaining lease terms of up to 10 years, some of which may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expense was $576,000 for the three months ended October 31, 2019, inclusive of period cost for short-term leases, not included in lease liabilities, of $222,000. Operating lease expense was $1,125,000 for the six months ended October 31, 2019, inclusive of period cost for short-term leases, not included in lease liabilities, of $457,000.
At October 31, 2019, the weighted average remaining lease term for the capitalized operating leases was 8.0 years and the weighted average discount rate was 4.1%. For finance leases, the weighted average remaining lease term was 5.9 years and the weighted average discount rate was 10.0%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable.
9

Future minimum lease payments of non-cancelable leases as of October 31, 2019:

|  | Operating |  | Financing
Remainder of fiscal 2020 |  | $ | 853 |  |  | $ | 16 |
2021 |  | 1,591 |  |  | 32 |
2022 |  | 1,543 |  |  | 32 |
2023 |  | 1,531 |  |  | 32 |
2024 |  | 1,246 |  |  | 31 |
Thereafter |  | 5,198 |  |  | 42 |
Total Minimum Lease Payments |  | $ | 11,962 |  |  | $ | 185 |
Imputed Interest |  | (2,049 | ) |  | (45 | )
Total |  | $ | 9,913 |  |  | $ | 140 |

I. Earnings Per Share
Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units (“RSUs”) under the Company’s various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 85,205 antidilutive RSUs and options outstanding at October 31, 2019. There were no antidilutive RSUs or options outstanding at October 31, 2018. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands):

| Three Months Ended October 31, |  | Six Months Ended October 31, |
| 2019 | 2018 |  | 2019 | 2018
Basic | 2,750 |  |  | 2,743 |  |  |  | 2,750 |  |  | 2,740 |  |
Dilutive effect of stock options and RSUs | — |  |  | 57 |  |  |  | — |  |  | 62 |  |
Weighted average common shares outstanding - diluted | 2,750 |  |  | 2,800 |  |  |  | 2,750 |  |  | 2,802 |  |

J. Stock Options and Share-based Compensation
Compensation costs related to stock options and other stock awards granted by the Company are charged against operating expenses during their vesting period, under ASC 718, “Compensation-Stock Compensation”. The Company granted 36,534 RSUs under the 2017 Omnibus Incentive Plan in June 2019. The RSUs include both a service and a performance component, vesting over a three year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three-year period, based on the ratio of cumulative days incurred to total days over the three year period. The Company recorded share-based compensation expense during the three and six months ended October 31, 2019 of $41,000 and $82,000, respectively, with the remaining estimated share-based compensation expense of $512,000 to be recorded over the remaining vesting periods.
K. Income Taxes
Income tax expense of $2,003,000 and $388,000 was recorded for the three months ended October 31, 2019 and 2018, respectively. Income tax expense of $2,172,000 and $783,000 was recorded for the six months ended October 31, 2019 and 2018, respectively. The effective tax rates were 1,267.7% and 22.0% for the three months ended October 31, 2019 and 2018, respectively. The effective tax rates were 428.4% and 21.4% for the six months ended October 31, 2019 and 2018, respectively. The increase in the effective tax rate for the three-month and six-month periods is primarily due to the change in the Company’s assertion regarding the reinvestment of foreign unremitted earnings and the impact of foreign earnings which are taxed at different tax rates than the US tax rate of 21%, and additional Global Intangible Low-Taxed Income ("GILTI") inclusion in the US.
Effective August 1, 2019, the Company elected to amend the indefinite reinvestment of foreign unremitted earnings position set forth by ASC 740-30-25-17 and dissolve the indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries.
10

The Company included a Dividend Distribution Tax withholding expense, imposed by the India Income Tax Department, at a rate of 20.6% for the three and six months ended October 31, 2019. This expense was comprised of $353,000 of taxes paid for the Kewaunee Labway India Pvt. Ltd. dividend distribution that was paid to the parent company and a $1,730,000 deferred tax liability for the global tax exposure related to all remaining historical unremitted earnings of these international subsidiaries as of October 31, 2019. The Company recorded all deferred tax assets and liabilities related to its outside basis differences in its foreign subsidiaries consistent with ASC 740.
L. Defined Benefit Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans during the three and six months ended October 31, 2019, and the Company does not expect any contributions to be paid during the remainder of the fiscal year. Contributions of $1,000,000 were paid to the plans during the six months ended October 31, 2018. The Company assumed an expected long-term rate of return of 7.75% for the periods ended October 31, 2019 and October 31, 2018. Pension expense consisted of the following (in thousands):

| Three Months Ended October 31, 2019 |  | Three Months Ended October 31, 2018
Service cost | $ | 0 |  |  | $ | 0 |
Interest cost | 208 |  |  | 215 |
Expected return on plan assets | (355 | ) |  | (362 | )
Recognition of net loss | 260 |  |  | 221 |
Net periodic pension expense | $ | 113 |  |  | $ | 74 |

| Six Months Ended October 31, 2019 |  | Six Months Ended October 31, 2018
Service cost | $ | 0 |  |  | $ | 0 |
Interest cost | 416 |  |  | 430 |
Expected return on plan assets | (710 | ) |  | (724 | )
Recognition of net loss | 520 |  |  | 442 |
Net periodic pension expense | $ | 226 |  |  | $ | 148 |

M. Segment Information
The Company’s operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company’s foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments.
The following tables provide financial information by business segments for the periods ended October 31, 2019 and 2018 (in thousands):

| Domestic Operations |  | International Operations |  | Corporate / Eliminations |  | Total
Three months ended October 31, 2019 |  |  |  |  |  |  |
Revenues from external customers | $ | 31,584 |  |  | $ | 8,138 |  |  | $ | — |  |  | $ | 39,722 |
Intersegment revenues | 907 |  |  | 641 |  |  | (1,548 | ) |  | — |
Earnings (loss) before income taxes | $ | 746 |  |  | $ | 501 |  |  | $ | (1,405 | ) |  | $ | (158 | )
Three months ended October 31, 2018 |  |  |  |  |  |  |
Revenues from external customers | $ | 30,622 |  |  | $ | 6,656 |  |  | $ | — |  |  | $ | 37,278 |
Intersegment revenues | 416 |  |  | 1,108 |  |  | (1,524 | ) |  | — |
Earnings (loss) before income taxes | $ | 2,837 |  |  | $ | 705 |  |  | $ | (1,782 | ) |  | $ | 1,760 |

11

| Domestic Operations |  | International Operations |  | Corporate / Eliminations |  | Total
Six months ended October 31, 2019 |  |  |  |  |  |  |
Revenues from external customers | $ | 60,871 |  |  | $ | 18,187 |  |  | $ | — |  |  | $ | 79,058 |
Intersegment revenues | 3,086 |  |  | 1,483 |  |  | (4,569 | ) |  | — |
Earnings (loss) before income taxes | $ | 2,306 |  |  | $ | 1,109 |  |  | $ | (2,908 | ) |  | $ | 507 |
Six months ended October 31, 2018 |  |  |  |  |  |  |
Revenues from external customers | $ | 66,692 |  |  | $ | 12,738 |  |  | $ | — |  |  | $ | 79,430 |
Intersegment revenues | 878 |  |  | 1,834 |  |  | (2,712 | ) |  | — |
Earnings (loss) before income taxes | $ | 5,945 |  |  | $ | 1,154 |  |  | $ | (3,446 | ) |  | $ | 3,653 |

N. Reclassifications
During the second quarter of fiscal year 2019, the Company changed its method of accounting for its Domestic segment’s inventory from the LIFO method to the FIFO method. The Company reclassified certain amounts in the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive income, the condensed consolidated statements of stockholders’ equity and the condensed consolidated statements of cash flows for the six-month period ended October 31, 2018 to conform to the current period format.
O. New Accounting Standards
In February 2016, the FASB issued ASU 2016-2, “Leases.” This guidance establishes a ROU model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company adopted this standard effective May 1, 2019. See Note H for a discussion of the impact of adoption of this standard.
In August 2018, the Commission adopted final rules pursuant to Commission Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule became effective on November 5, 2018. The Company adopted this final rule effective for the second quarter of fiscal 2019. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.
In February 2018, the FASB issued ASU 2018-2, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” This guidance provides the Company with an option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act (the "2017 Tax Act") from accumulated other comprehensive income to retained earnings. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company adopted this standard effective May 1, 2019 and did not elect to reclassify tax effects as a result of tax reform; therefore, the adoption did not have a significant impact on the Company’s consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company’s consolidated financial position or results of operations.
P. Subsequent Events
12

In December 2019, the Company initiated a restructuring, which included the addition of a new Vice President of Information Technology to lead the transformation and modernization of the Company's information systems, and a reduction in workforce primarily in its domestic operations to reduce operating expenses on an ongoing basis. This restructuring also included a plan for closure of the Company’s subsidiary in China, a commercial sales organization for the Company’s products in China. The Company expects to record a charge in the range of $385,000 to $535,000 in the third quarter of fiscal year 2020 as a result of the restructuring consisting primarily of hiring and relocation expenses and one-time termination benefits for employee severance and benefits. The majority of these expenses are expected to be paid during the third quarter of fiscal year 2020.

Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2019 Annual Report to Stockholders contains management’s discussion and analysis of the Company’s financial condition and results of operations as of and for the year ended April 30, 2019. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2019. The analysis of results of operations compares the three and six months ended October 31, 2019 with the comparable periods of the prior year.
Results of Operations
Sales for the quarter were $39,722,000, a 6.6% increase from sales of $37,278,000 in the comparable period of the prior year. Domestic sales for the quarter were $31,584,000, up 3.1% from sales of $30,622,000 in the comparable period of the prior year. International sales for the quarter were $8,138,000, up 22.3% from sales of $6,656,000 in the comparable period of the prior year. The increase in Domestic sales for the quarter was a result of increased activity in the Company's direct sales markets offsetting weakness in dealer activity. International sales increased year over year as a result of continued deliveries of a large, strategic order in the Middle East.
Sales for the six months ended October 31, 2019 were $79,058,000, a 0.5% decrease from sales of $79,430,000 in the comparable period of the prior year. Domestic sales for the six-month period were $60,871,000, down 8.7% from sales of $66,692,000 in the comparable period of the prior year. International sales for the quarter were $18,187,000, up 42.8% from sales of $12,738,000 in the comparable period of the prior year.
The Company’s order backlog was $92 million at October 31, 2019, as compared to $101 million at October 31, 2018, and $101 million at April 30, 2019. The Company continues to have a strong volume of outstanding quotations globally and is aggressively pursuing these projects.
The gross profit margin for the three months ended October 31, 2019 was 15.9% of sales, as compared to 20.6% of sales in the comparable quarter of the prior year. The gross profit margin for the six months ended October 31, 2019 was 16.8% of sales, as compared to 19.2% of sales in the comparable period of the prior year. The decrease in gross profit margin percentage for the three and six months ended October 31, 2019 was a result of a number of low margin orders that the Company aggressively pursued and secured over the past year, and a strategic Middle East order aggressively secured over two years ago at lower than normal margins.
Operating expenses for the three months ended October 31, 2019 were $6,355,000, or 16.0% of sales, as compared to $5,963,000, or 16.0% of sales, in the comparable period of the prior year. Operating expenses for the six months ended October 31, 2019 were $12,525,000, or 15.8% of sales, as compared to $11,726,000, or 14.8% of sales, in the comparable period of the prior year. The increase in operating expenses for the three and six months ended October 31, 2019 related primarily to higher operating costs in the international segment as the Company made investments in capabilities intended to strengthen its position in the India market.
Interest expense was $135,000 and $302,000 for the three and six months ended October 31, 2019, as compared to $91,000 and $182,000 for the comparable periods of the prior year. The changes in interest expense were primarily attributable to changes in borrowing levels.
Income tax expense of $2,003,000 and $388,000 was recorded for the three months ended October 31, 2019 and 2018, respectively. For the six months ended October 31, 2018 and 2019, income tax expense was $2,172,000 and $783,000, respectively. The effective tax rates were 1,267.7% and 22.0% for the three months ended October 31, 2019 and 2018, respectively. The effective tax rates were 428.4% and 21.4% for the six months ended October 31, 2019 and 2018, respectively. The increase in the effective tax rate for the three-month and six-month periods reflects the impact of foreign earnings which were taxed at different tax rates than the US tax rate of 21% and additional GILTI inclusion in the US.
13

As part the Company’s revised global treasury management strategy, the Company elected to amend the indefinite reinvestment of foreign unremitted earnings position set forth by ASC 740 and dissolve the indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries. Revoking this election provides the Company more flexibility in treasury management to invest in projects intended to improve the Company’s operating performance.
The Company included a Dividend Distribution Tax withholding expense, imposed by the India Income Tax Department, at a rate of 20.6% for the three and six months ended October 31, 2019. This expense was comprised of $353,000 of taxes paid for the Kewaunee Labway India Pvt. Ltd. dividend distribution that was paid to the parent company and a $1,730,000 deferred tax liability for the global tax exposure related to all remaining historical unremitted earnings of these international subsidiaries as of October 31, 2019. The Company will record the Dividend Distribution Tax on all future Kewaunee Labway India Pvt. Ltd. earnings at an estimated rate of 20.6% in addition to the corporate income taxes.
Noncontrolling interests related to the Company’s subsidiaries not 100% owned by the Company reduced net earnings by $17,000 and $42,000 for the three and six months ended October 31, 2019, respectively, as compared to $40,000 and $49,000 for the comparable periods of the prior year. The change in the net earnings attributable to the noncontrolling interest in the current period was due to changes in earnings of the subsidiary in the related period.
Net loss was $2,178,000, or $0.79 per diluted share, for the three months ended October 31, 2019, compared to net earnings of $1,332,000, or $0.48 per diluted share, in the prior year period. Net loss of $1,707,000, or $0.62 per diluted share, were reported for the six months ended October 31, 2019, compared to net earnings of $2,821,000, or $1.01 per diluted share, in the prior year period.
Liquidity and Capital Resources
Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current year, including capital expenditures.
The Company had working capital of $30,841,000 at October 31, 2019, compared to $32,624,000 at April 30, 2019. The ratio of current assets to current liabilities was 2.0-to-1.0 at October 31, 2019, compared to 2.0-to-1.0 at April 30, 2019. At October 31, 2019, advances of $6.8 million were outstanding under the Company’s bank revolving credit facility, compared to advances of $9.5 million outstanding as of April 30, 2019. The Company had standby letters of credit outstanding of $344,000 at October 31, 2019 compared to standby letters of credit outstanding of $5.2 million at April 30, 2019. Amounts available under the $20 million revolving credit facility were $12.9 million and $5.3 million at October 31, 2019 and April 30, 2019, respectively. Total borrowings and interest rate swaps were $6.9 million at October 31, 2019, compared to $10.9 million at April 30, 2019. As previously reported in the reports on Form 8-K filed by the Company on June 21, 2019 and July 11, 2019, and in Note 4 of the Notes to the Consolidated Financial Statements included in the Company's 2019 Annual Report on Form 10-K, during the six months ended October 31, 2019, the Company amended its credit facility and entered into a restated security agreement.
In September 2019, the Company paid off its term loan and terminated its interest rate swap agreements. On December 13, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change to an asset based lending arrangement based on eligible accounts receivable and inventory, with the available amount not to exceed $20 million through January 31, 2020, and with such maximum amount reduced to $15 million thereafter. This amendment replaced the prior financial covenants with new financial covenants, including minimum monthly liquidity and EBITDA requirements. Additionally, a requirement for the repatriation of foreign cash and restrictions on the payments of dividends was added. At October 31, 2019, the Company was in compliance with all of the then-applicable financial covenants of the agreement.
The Company’s operations provided cash of $4,496,000 during the six months ended October 31, 2019. Cash was provided primarily by operations and decreases in receivables of $1,171,000 and inventory of $2,428,000. During the six months ended October 31, 2019, the Company used net cash of $715,000 in investing activities, all of which was used for capital expenditures. The Company’s financing activities used cash of $5,174,000 during the six months ended October 31, 2019, primarily for reductions in short-term borrowings of $2,753,000, cash dividends of $1,045,000 paid to stockholders, cash dividends paid to minority interest holders of $89,000 and repayments of $1,273,000 of long-term debt.
Outlook
14

The Company’s ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. Looking forward, the third quarter is typically the Company's most challenging quarter as there are fewer manufacturing days than other quarters due to the holidays in the United States and construction projects generally slow down at the end of the calendar year. Our goal is to ensure that the Company's fourth quarter production load is full in order to operate our manufacturing facilitates efficiently, which in turn should drive recovery in profitability.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This report contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Many important factors that could cause such differences are described under the caption “Risk Factors” in Item 1A in the Company’s 2019 Annual Report on Form 10-K and in Quarterly Reports on Form 10-Q subsequently filed by the Company. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 3. | Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2019.

Item 4. | Controls and Procedures

(a) Evaluation of disclosure controls and procedures
An evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of October 31, 2019. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of October 31, 2019, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) Changes in internal controls
There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
15

PART II. OTHER INFORMATION

Item 6. | Exhibits

10.1 |  | Eighth Amendment to Credit and Security Agreement and Fourth Amendment to Revolving Line of Credit Note dated as of December 13, 2019 (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on December 16, 2019). |
10.83* |  | Employment Agreement dated as of October 28, 2019 between Kewaunee Scientific Corporation and Mandar Ranade. |
31.1 |  | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 |  | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 |  | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2 |  | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS |  | XBRL Instance Document |
101.SCH |  | XBRL Taxonomy Extension Schema Document |
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document |

* The referenced exhibit is a management contract or compensatory plan or arrangement.
16

SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | KEWAUNEE SCIENTIFIC CORPORATION (Registrant)
Date: December 16, 2019 |  | By | /s/ Donald T. Gardner III
|  |  | Donald T. Gardner III
|  |  | (As duly authorized officer and Vice President, Finance and Chief Financial Officer)

17